Skip to Content

Qinlock Side Effects

Generic Name: ripretinib

Medically reviewed by Last updated on June 1, 2020.

Note: This document contains side effect information about ripretinib. Some of the dosage forms listed on this page may not apply to the brand name Qinlock.

For the Consumer

Applies to ripretinib: oral tablet


Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • severe stomach pain, nausea, or vomiting;

  • severe headache, blurred vision, pounding in your neck or ears;

  • pain, blisters, bleeding, or severe rash in the palms of your hands or the soles of your feet;

  • heart problems--tiredness, feeling short of breath, swollen veins in the sides of your neck, swelling in your stomach or lower legs;

  • low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or

  • skin changes--a new wart, a skin sore or red bump that bleeds or does not heal, or any change in the size or color of a mole.

Common side effects may include:

  • nausea, vomiting, stomach pain, loss of appetite;

  • diarrhea, constipation;

  • tiredness;

  • muscle pain;

  • thinning hair, hair loss;

  • abnormal blood tests; or

  • severe rash on your hands or feet.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to ripretinib: oral tablet


Very common (10% or more): Neutropenia (42%), thrombocytopenia (40%), increased activated partial thromboplastin time anemia (24%), increased INR (21%), lymphopenia (13%), febrile neutropenia (11%), decreased neutrophil count (10%)[Ref]


Very common (10% or more): Myalgia (32%), arthralgia (18%), muscle spasms (15%)[Ref]


Very common (10% or more): Anorexia (27%), triglycerides increased (26%), phosphate decreased (26%), triglycerides increased (26%), calcium decreased (23%), weight loss (19%), weight loss (19%), sodium decreased (17%)[Ref]


Very common (10% or more): Blood bilirubin increased (21%), ALT increased (12%)[Ref]


Very common (10% or more): New primary cutaneous malignancies (e.g., cutaneous squamous cell carcinoma (cuSCC), keratoacanthoma, melanoma[Ref]


Very common (10% or more): Dyspnea (13%)[Ref]


Very common (10% or more): Fatigue (42%), CPK increased (21%), peripheral edema (17%), asthenia (13%)[Ref]

Nervous system

Very common (10% or more): Headache (19%)[Ref]


Very common (10% or more): Creatinine increased (16%)[Ref]


Very common (10% or more): Hypertension (14%)

Common (1% to 10%): Cardiac dysfunction (e.g., cardiac failure, acute left ventricular failure, diastolic dysfunction, ventricular hypertrophy)[Ref]


Very common (10% or more): Alopecia (52%), palmar-plantar erythrodysesthesia syndrome (PPES) (21%), dry skin (13%), pruritus (11%)[Ref]


Very common (10% or more): Nausea (39%), abdominal pain (36%), constipation (34%), lipase increased (32%), diarrhea (28%), vomiting (21%), serum amylase increased (13%), stomatitis (11%)[Ref]


1. "Product Information. Qinlock (ripretinib)." Deciphera Pharmaceuticals, Waltham, MA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.